Over the past 12 months, 6 insiders at Amylyx Pharmaceuticals, Inc. filed 31 open-market SEC Form 4 transactions on AMLX: 2 purchases worth $152K and 29 sales worth $7.9M. Insiders have been net sellers over this period. The most recent filing was on Jul 10, 26.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Jul 10, 26 | Gina MazzarielloChief Legal Officer | SELL | 15.0K | $17.61 | $264K |
| Jul 9, 26 | Gina MazzarielloChief Legal Officer | SELL | 15.0K | $18.32 | $275K |
| May 21, 26 | Karen Firestone | BUY | 3.8K | $13.51 | $51K |
| Mar 2, 26 | Camille L BedrosianChief Medical Officer | SELL | 6.5K | $14.58 | $94K |
| Mar 2, 26 | Joshua B CohenCo-Chief Executive Officer | SELL | 29.3K | $14.48 | $424K |
| Mar 2, 26 | James M FratesChief Financial Officer | SELL | 7.9K | $14.52 | $115K |
| Mar 2, 26 | Justin B. KleeCo-Chief Executive Officer | SELL | 29.3K | $14.47 | $424K |
| Mar 2, 26 | Gina MazzarielloChief Legal Officer | SELL | 6.8K | $14.52 | $99K |
| Feb 23, 26 | Gina MazzarielloChief Legal Officer | SELL | 3.4K | $14.14 | $48K |
| Feb 2, 26 | Joshua B CohenCo-Chief Executive Officer | SELL | 15.5K | $14.68 | $228K |
| Feb 2, 26 | James M FratesChief Financial Officer | SELL | 3.6K | $14.65 | $52K |
| Feb 2, 26 | Justin B. KleeCo-Chief Executive Officer | SELL | 15.5K | $14.69 | $228K |
| Feb 2, 26 | Gina MazzarielloChief Legal Officer | SELL | 3.4K | $14.65 | $51K |
| Jan 16, 26 | Joshua B CohenCo-Chief Executive Officer | SELL | 2.0K | $13.83 | $27K |
| Jan 16, 26 | Justin B. KleeCo-Chief Executive Officer | SELL | 2.0K | $13.89 | $28K |
| Jan 15, 26 | Joshua B CohenCo-Chief Executive Officer | SELL | 136.2K | $13.59 | $1.9M |
| Jan 15, 26 | Justin B. KleeCo-Chief Executive Officer | SELL | 136.2K | $13.58 | $1.8M |
| Jan 6, 26 | Joshua B CohenCo-Chief Executive Officer | SELL | 7.7K | $11.09 | $86K |
| Jan 6, 26 | James M FratesChief Financial Officer | SELL | 3.3K | $11.11 | $37K |
| Jan 6, 26 | Justin B. KleeCo-Chief Executive Officer | SELL | 7.7K | $11.09 | $86K |
| Dec 23, 25 | Karen FirestoneDirector | BUY | 8.1K | $12.45 | $101K |
| Dec 1, 25 | Camille L BedrosianChief Medical Officer | SELL | 6.6K | $14.35 | $94K |
| Sep 30, 25 | Camille L BedrosianChief Medical Officer | SELL | 12.0K | $14.58 | $176K |
| Sep 30, 25 | Joshua B CohenCo-Chief Executive Officer | SELL | 29.7K | $15.00 | $426K |
| Sep 30, 25 | James M FratesChief Financial Officer | SELL | 10.6K | $14.65 | $155K |
| Sep 30, 25 | Justin B. KleeCo-Chief Executive Officer | SELL | 29.8K | $15.01 | $428K |
| Sep 30, 25 | Gina MazzarielloChief Legal Officer | SELL | 8.8K | $14.58 | $129K |
| Aug 13, 25 | Gina MazzarielloChief Legal Officer | SELL | 15.0K | $8.34 | $125K |
| Aug 12, 25 | Gina MazzarielloChief Legal Officer | SELL | 15.0K | $8.07 | $121K |
| Mar 31, 25 | Camille L BedrosianChief Medical Officer | SELL | 12.4K | $3.47 | $43K |
| Mar 31, 25 | Joshua B CohenCo-Chief Executive Officer | SELL | 21.5K | $3.47 | $75K |
| Mar 31, 25 | James M FratesChief Financial Officer | SELL | 10.9K | $3.47 | $38K |
| Mar 31, 25 | Justin B. KleeCo-Chief Executive Officer | SELL | 21.5K | $3.46 | $74K |
| Mar 31, 25 | Gina MazzarielloChief Legal Officer | SELL | 9.2K | $3.48 | $32K |
| Mar 20, 25 | Bernhardt G ZeiherDirector | BUY | 10.0K | $3.70 | $37K |
| Mar 3, 25 | Joshua B CohenCo-Chief Executive Officer | SELL | 4.6K | $3.17 | $15K |
| Mar 3, 25 | Justin B. KleeCo-Chief Executive Officer | SELL | 4.6K | $3.15 | $14K |
| Mar 3, 25 | Gina MazzarielloChief Legal Officer | SELL | 1.6K | $3.12 | $5K |
| Feb 24, 25 | Gina MazzarielloChief Legal Officer | SELL | 4.2K | $3.15 | $13K |
| Feb 3, 25 | Joshua B CohenCo-Chief Executive Officer | SELL | 11.9K | $3.47 | $41K |
| Feb 3, 25 | Justin B. KleeCo-Chief Executive Officer | SELL | 11.9K | $3.47 | $41K |
| Feb 3, 25 | Gina MazzarielloChief Legal Officer | SELL | 3.7K | $3.49 | $13K |
| Jan 6, 25 | Joshua B CohenCo-Chief Executive Officer | SELL | 7.5K | $4.05 | $30K |
| Jan 6, 25 | Justin B. KleeCo-Chief Executive Officer | SELL | 7.5K | $4.04 | $30K |
| Dec 2, 24 | Camille L BedrosianChief Medical Officer | SELL | 5.4K | $5.54 | $30K |
| Sep 30, 24 | Camille L BedrosianChief Medical Officer | SELL | 11.4K | $3.20 | $37K |
| Sep 30, 24 | Joshua B CohenCo-Chief Executive Officer | SELL | 18.6K | $3.20 | $59K |
| Sep 30, 24 | Justin B. KleeCo-Chief Executive Officer | SELL | 18.6K | $3.20 | $59K |
| Sep 30, 24 | Gina MazzarielloChief Legal Officer | SELL | 8.7K | $3.20 | $28K |
| Sep 12, 24 | James M FratesChief Financial Officer | BUY | 40.0K | $2.53 | $101K |
Over the past 12 months, insiders at Amylyx Pharmaceuticals, Inc. filed 2 open-market purchases worth $152K and 29 sales worth $7.9M on AMLX, which makes them net sellers over the period. The most recent Form 4 was filed on Jul 10, 26.
The largest recent open-market AMLX insider purchase in our data was $101K by James M Frates, Chief Financial Officer, filed on Sep 12, 24.
6 different insiders at Amylyx Pharmaceuticals, Inc. filed open-market SEC Form 4 transactions on AMLX over the last 12 months.
InsiderTape plots every AMLX insider buy and sell directly on the price chart and flags new SEC Form 4 filings as they arrive, with cluster detection and buy/sell pressure. The data updates daily from SEC EDGAR.
InsiderTape plots every Amylyx Pharmaceuticals, Inc. insider buy and sell on the price chart, with buy/sell pressure, cluster detection, and alerts the moment new Form 4s hit. Start a free 7-day trial, cancel anytime.
Does it work? In five years of data, insider clusters beat the Russell 2000 about 60% of the time and the CFO's buy was the sharpest signal of all. See the backtest →
START FREE TRIAL →